MXPA04006198A - Metodo para suministrar sistemicamente inhibidores selectivos de la recaptacion de serotonina. - Google Patents
Metodo para suministrar sistemicamente inhibidores selectivos de la recaptacion de serotonina.Info
- Publication number
- MXPA04006198A MXPA04006198A MXPA04006198A MXPA04006198A MXPA04006198A MX PA04006198 A MXPA04006198 A MX PA04006198A MX PA04006198 A MXPA04006198 A MX PA04006198A MX PA04006198 A MXPA04006198 A MX PA04006198A MX PA04006198 A MXPA04006198 A MX PA04006198A
- Authority
- MX
- Mexico
- Prior art keywords
- fluoxetine
- ssri
- weight
- ssris
- pharmaceutically acceptable
- Prior art date
Links
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title abstract description 20
- 229960002464 fluoxetine Drugs 0.000 claims abstract description 100
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims abstract description 98
- 239000000203 mixture Substances 0.000 claims abstract description 68
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims abstract description 51
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 229940076279 serotonin Drugs 0.000 claims description 6
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 5
- 229960002296 paroxetine Drugs 0.000 claims description 5
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 5
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 4
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 4
- 229940124639 Selective inhibitor Drugs 0.000 claims description 4
- 229960001653 citalopram Drugs 0.000 claims description 4
- 229960004038 fluvoxamine Drugs 0.000 claims description 4
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 229960002073 sertraline Drugs 0.000 claims description 4
- 230000000697 serotonin reuptake Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 14
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 abstract description 10
- 238000013270 controlled release Methods 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 208000035475 disorder Diseases 0.000 abstract description 6
- 208000019695 Migraine disease Diseases 0.000 abstract description 5
- 208000020401 Depressive disease Diseases 0.000 abstract description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract description 4
- 230000001839 systemic circulation Effects 0.000 abstract description 4
- 208000000094 Chronic Pain Diseases 0.000 abstract description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract description 2
- 208000002193 Pain Diseases 0.000 abstract description 2
- 201000009032 substance abuse Diseases 0.000 abstract description 2
- 231100000736 substance abuse Toxicity 0.000 abstract description 2
- 208000011117 substance-related disease Diseases 0.000 abstract description 2
- 206010027603 Migraine headaches Diseases 0.000 abstract 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 abstract 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 24
- -1 trifluoropropylmethyl Chemical group 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 239000003814 drug Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 229920001971 elastomer Polymers 0.000 description 10
- 239000000806 elastomer Substances 0.000 description 10
- WIQRCHMSJFFONW-UHFFFAOYSA-N norfluoxetine Chemical compound C=1C=CC=CC=1C(CCN)OC1=CC=C(C(F)(F)F)C=C1 WIQRCHMSJFFONW-UHFFFAOYSA-N 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000004205 dimethyl polysiloxane Substances 0.000 description 8
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 229940044953 vaginal ring Drugs 0.000 description 8
- 239000006213 vaginal ring Substances 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 230000002335 preservative effect Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 6
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- 239000002480 mineral oil Substances 0.000 description 6
- 235000010446 mineral oil Nutrition 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
- 229920000881 Modified starch Polymers 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000013583 drug formulation Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229960001631 carbomer Drugs 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 229940008099 dimethicone Drugs 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- 206010027599 migraine Diseases 0.000 description 4
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000032841 Bulimia Diseases 0.000 description 3
- 206010006550 Bulimia nervosa Diseases 0.000 description 3
- 208000034423 Delivery Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000009677 vaginal delivery Effects 0.000 description 3
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 description 2
- JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 2
- HCYAFALTSJYZDH-FIBGUPNXSA-N 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n-(trideuteriomethyl)propan-1-amine Chemical compound C1CC2=CC=CC=C2N(CCCNC([2H])([2H])[2H])C2=CC=CC=C21 HCYAFALTSJYZDH-FIBGUPNXSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229910018557 Si O Inorganic materials 0.000 description 2
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 229920006243 acrylic copolymer Polymers 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 2
- 229960001083 diazolidinylurea Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 230000003982 neuronal uptake Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Inorganic materials [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229920001935 styrene-ethylene-butadiene-styrene Polymers 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229940047493 celexa Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940009622 luvox Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229940100992 sarafem Drugs 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940100459 steareth-20 Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000000629 tetracyclic antidepressant agent Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000012974 tin catalyst Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000607 toxicokinetics Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 125000000725 trifluoropropyl group Chemical group [H]C([H])(*)C([H])([H])C(F)(F)F 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940020965 zoloft Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34325401P | 2001-12-21 | 2001-12-21 | |
| US10/095,558 US7005138B2 (en) | 2001-12-21 | 2002-03-12 | Method of systematically delivering SSRIs |
| PCT/US2002/040808 WO2003055424A1 (en) | 2001-12-21 | 2002-12-20 | METHOD OF SYSTEMICALLY DELIVERING SSRIs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04006198A true MXPA04006198A (es) | 2005-04-19 |
Family
ID=26790345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04006198A MXPA04006198A (es) | 2001-12-21 | 2002-12-20 | Metodo para suministrar sistemicamente inhibidores selectivos de la recaptacion de serotonina. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7005138B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1465563A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2005517669A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2002357352B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2471039A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MXPA04006198A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2003055424A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040043071A1 (en) * | 2002-06-21 | 2004-03-04 | Pauletti Giovanni M. | Intravaginal mucosal or transmucosal delivery of antimigraine and antinausea drugs |
| MX2013000002A (es) * | 2001-07-27 | 2013-04-29 | Teva Womens Health Inc | Metodos de tratamiento de condiciones patologicas asociadas con vejiga hiperactiva. |
| US7544681B2 (en) | 2001-09-27 | 2009-06-09 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| US20050101666A1 (en) * | 2003-11-07 | 2005-05-12 | H. Lundbeck A/S | Method of treating premenstrual dysphoric disorder with escitalopram |
| IL159273A0 (en) * | 2003-12-09 | 2004-06-01 | Transpharma Medical Ltd | Transdermal delivery system for sustained release of polypeptides |
| JP5265359B2 (ja) | 2005-08-11 | 2013-08-14 | マサチューセッツ インスティテュート オブ テクノロジー | 膀胱内薬物送達デバイスおよび方法 |
| WO2008010223A2 (en) * | 2006-07-17 | 2008-01-24 | Ramot At Tel Aviv University Ltd. | Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders |
| US20090209622A1 (en) * | 2006-11-21 | 2009-08-20 | Smoller Jordan W | Diagnosis of anxiety disorders |
| WO2008112641A2 (en) * | 2007-03-09 | 2008-09-18 | New York University | Methods and compositions for treating thalamocortical dysrhythmia |
| FI7960U1 (fi) | 2007-04-27 | 2008-07-28 | Bayer Schering Pharma Oy | Implantoitavan annostelusysteemin membraanikuori |
| WO2009003279A1 (en) * | 2007-06-29 | 2009-01-08 | Carmanah Technologies Corp. | Intelligent area lighting system |
| US9586035B2 (en) * | 2007-12-11 | 2017-03-07 | Massachusetts Institute Of Technology | Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens |
| US9138430B2 (en) * | 2007-12-27 | 2015-09-22 | Mylan Specialty L.P. | Formulation and method for the release of paroxetine in the large intestine |
| US8207369B2 (en) | 2008-02-11 | 2012-06-26 | Ramot At Tel-Aviv University Ltd. | Conjugates for treating neurodegenerative diseases and disorders |
| EA201170297A1 (ru) | 2008-08-09 | 2011-08-30 | Массачусетс Инститьют Оф Текнолоджи | Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей |
| US20100040671A1 (en) * | 2008-08-12 | 2010-02-18 | Ahmed Salah U | Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof |
| FI121000B (fi) * | 2008-11-19 | 2010-06-15 | Bayer Schering Pharma Oy | Intravaginaalinen antojärjestelmä ja menetelmä sen valmistamiseksi |
| AU2010265863C1 (en) | 2009-06-26 | 2012-11-01 | Taris Biomedical Llc | Implantable drug delivery devices and methods of making the same |
| US9017312B2 (en) | 2009-09-10 | 2015-04-28 | Taris Biomedical Llc | Implantable device for controlled drug delivery |
| WO2011104637A2 (en) | 2010-02-24 | 2011-09-01 | Ramot At Tel-Aviv University Ltd. | Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same |
| SG10201504864UA (en) * | 2010-06-22 | 2015-07-30 | Teva Womens Health Inc | Intravaginal devices comprising anticholinergic agents, and methods of making thereof |
| US8916610B2 (en) | 2010-09-22 | 2014-12-23 | Ramot At Tel-Aviv University Ltd. | Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same |
| CA2823783C (en) | 2011-01-10 | 2023-03-21 | Taris Biomedical, Inc. | Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding |
| RU2598057C2 (ru) | 2011-02-04 | 2016-09-20 | ТАРИС Биомедикал ЛЛК | Имплантируемое устройство для контролируемого высвобождения лекарственного средства с низкой растворимостью |
| GB201115592D0 (en) * | 2011-09-09 | 2011-10-26 | Vivosens Medical Gmbh | Flexible ring pessary |
| US20150196533A1 (en) * | 2012-07-02 | 2015-07-16 | The General Hospital Corporation | Method for concurrent treatment of pain and depression |
| USD703319S1 (en) * | 2012-09-07 | 2014-04-22 | Vivosensmedical Gmbh | Ring pessary |
| HUE072250T2 (hu) | 2013-03-15 | 2025-11-28 | Taris Biomedical Llc | Gyógyszeradagoló eszközök gyógyszeráteresztõ résszel |
| ES2956840T3 (es) | 2013-08-19 | 2023-12-29 | Taris Biomedical Llc | Dispositivos de administración de fármacos de múltiples unidades |
| CN104546267B (zh) * | 2015-01-13 | 2017-01-04 | 安徽农业大学 | 一种犬用宫外节育装置及其节育方法 |
| ES2985998T3 (es) * | 2015-01-30 | 2024-11-08 | Ligalli B V | Dispositivo de administración vaginal de fármacos |
| KR102658706B1 (ko) | 2015-04-23 | 2024-04-17 | 타리스 바이오메디컬 엘엘씨 | 약물-투과성 성분을 구비한 약물 전달 장치 및 방법 |
| CA189648S (en) | 2019-03-08 | 2022-01-28 | Rite Hite Holding Corp | Mounting device for fan and light |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3711602A (en) * | 1970-10-30 | 1973-01-16 | Crown Zellerbach Corp | Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso |
| IL48277A (en) * | 1974-10-18 | 1978-03-10 | Schering Ag | Vaginal ring |
| US4442113A (en) * | 1981-05-07 | 1984-04-10 | A/S Ferrosan | Long-term weight reduction of obese patients using femoxetine |
| JPH0984855A (ja) * | 1995-09-25 | 1997-03-31 | Kyoto Yakuhin Kogyo Kk | 直腸または膣への薬物投与用のエアゾール製剤 |
| GB9522403D0 (en) * | 1995-11-01 | 1996-01-03 | Hoechst Roussel Ltd | Intravaginal drug delivery device |
| ES2227707T3 (es) * | 1996-07-15 | 2005-04-01 | Alza Corporation | Nuevas formulaciones para la administracion transdermica de acetato de fluoxetina y de maleato de fluoxetina. |
| EP0927034A1 (en) * | 1996-09-19 | 1999-07-07 | American Home Products Corporation | Method of treating urinary incontinence |
| US6039968A (en) * | 1997-06-24 | 2000-03-21 | Hoechst Marion Roussel | Intravaginal drug delivery device |
| IL133080A0 (en) * | 1997-07-01 | 2001-03-19 | Pfizer | Sertraline salts and sustained-release dosage forms of sertraline |
| US6248358B1 (en) * | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
| US6228864B1 (en) * | 1997-10-28 | 2001-05-08 | Vivus, Inc. | Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation |
| AU765603C (en) * | 1998-04-14 | 2004-08-05 | General Hospital Corporation, The | Methods for treating neuropsychiatric disorders |
| CA2332253A1 (en) * | 1998-05-21 | 1999-11-25 | Eli Lilly And Company | Combination therapy for treatment of depression |
| US6331571B1 (en) * | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| US6342533B1 (en) * | 1998-12-01 | 2002-01-29 | Sepracor, Inc. | Derivatives of (−)-venlafaxine and methods of preparing and using the same |
| US6239162B1 (en) | 1999-05-17 | 2001-05-29 | St. Elizabeth's Medical Center | Method for treating depression |
| HK1048956B (zh) * | 1999-05-27 | 2006-07-28 | 阿库斯菲尔公司 | 多孔药物基质及其制造方法 |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| US6264973B1 (en) * | 1999-08-26 | 2001-07-24 | Fei Enterprises, Ltd. | Apparatus and method for anesthetizing the cervical region of a female |
| US20020192302A1 (en) * | 1999-12-16 | 2002-12-19 | Tsung-Min Hsu | Transdermal and topical administration of antidepressant drugs using basic enhancers |
| GB0009914D0 (en) * | 2000-04-20 | 2000-06-07 | Metris Therapeutics Limited | Device |
| CN1289064C (zh) * | 2001-08-31 | 2006-12-13 | 先灵有限责任公司 | 药物输送体系 |
| NZ591627A (en) * | 2001-12-05 | 2012-09-28 | Teva Womens Health Inc | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
-
2002
- 2002-03-12 US US10/095,558 patent/US7005138B2/en not_active Expired - Fee Related
- 2002-12-20 WO PCT/US2002/040808 patent/WO2003055424A1/en not_active Ceased
- 2002-12-20 MX MXPA04006198A patent/MXPA04006198A/es active IP Right Grant
- 2002-12-20 CA CA002471039A patent/CA2471039A1/en not_active Abandoned
- 2002-12-20 JP JP2003556003A patent/JP2005517669A/ja active Pending
- 2002-12-20 AU AU2002357352A patent/AU2002357352B2/en not_active Ceased
- 2002-12-20 EP EP02805965A patent/EP1465563A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002357352A1 (en) | 2003-07-15 |
| AU2002357352B2 (en) | 2007-09-06 |
| JP2005517669A (ja) | 2005-06-16 |
| WO2003055424A1 (en) | 2003-07-10 |
| CA2471039A1 (en) | 2003-07-10 |
| US7005138B2 (en) | 2006-02-28 |
| US20030133977A1 (en) | 2003-07-17 |
| EP1465563A1 (en) | 2004-10-13 |
| EP1465563A4 (en) | 2010-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002357352B2 (en) | Method of systemically delivering SSRIs | |
| JP5986149B2 (ja) | 女性の尿失禁を治療するための用具および方法 | |
| US20020161352A1 (en) | Vaginal ring preparation and application | |
| CA2383785C (en) | Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | |
| KR20070111510A (ko) | 내파열성 서방형 투여 형태 | |
| AU2001245901A1 (en) | Device and method for treating urinary incontinence in females | |
| US20050197651A1 (en) | Vaginal ring preparation and its application | |
| JP2025510716A (ja) | シリコーン材料、シリコーンチューブ、インプラント、医薬組成物、薬物放出量の測定方法 | |
| Kumar et al. | Modern aspects of suppositories: A review | |
| KR20060084864A (ko) | 에스트로겐 화합물 및 프로게스테론 화합물로 이루어진호르몬 조성물 | |
| CN102000339A (zh) | 缓释释药的药物载体 | |
| KR100297212B1 (ko) | 직장투여용조성물 | |
| CN102000341A (zh) | 在栓剂组合物中的聚氧化乙烯及基质型表面活性剂 | |
| US20070281926A1 (en) | Rectal Composition | |
| AU2005290532A1 (en) | Pharmaceutical composition for xerophthalmia and xerostomia treatment | |
| KR20060123329A (ko) | 월경 곤란증의 예방 및/또는 치료제 | |
| WO2006098371A1 (ja) | 子宮内膜症および子宮腺筋症の治療剤および予防剤 | |
| HK1053254B (en) | Device and method for treating urinary incontinence in females | |
| CN101693026A (zh) | 单硝酸异山梨酯的新用途 | |
| HK1091418B (en) | Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | |
| HK1050484A1 (en) | Clonidine preparations | |
| HK1050484B (en) | Clonidine preparations | |
| HK1110789A (en) | Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| HC | Change of company name or juridical status |